Posts

AbbVie Inks $745M Deal with Haisco for Two Acute Pain Assets

on
AbbVie agreed to pay $30 million upfront to Haisco Pharmaceutical Group for ex-China rights to two non-opioid NaV1.8 inhibitor pain candidates: HSK55718 (Phase 1 IV) and HSK51155 (preclinical oral). The deal includes $10 million in near-term milestones and up to $705 million in additional milestones, plus high-single-digit royalties on net sales. AbbVie will fund R&D costs through clinical proof of concept; Haisco retains Greater China rights. Announced via April 13 Chinese filing, aligning with Haisco's international expansion strategy. Competitive landscape includes Vertex's approved Journavx and Eli Lilly's acquisition in NaV1.8 space. 1 4 Sources: 1. https://www.fiercebiotech.com/biotech/abbvie-inks-715m-deal-chinese-biotech-haisco-two-acute-pain-assets 4. https://finviz.com/quote.ashx?t=ABBV

Revolution Medicines Advances Daraxonrasib in Phase 3 Pancreatic Cancer Trial After Hitting Key Goals

on

IDEAYA and Servier Report Positive Phase 2/3 Trial Results for Darovasertib in Metastatic Uveal Melanoma, Paving Way for FDA Filing

on

Allogene's Off-the-Shelf CAR-T Cema-Cel Shows Early Promise in Erasing Lingering Lymphoma Cells

on

GSK CEO's 'Scientific Courage' Propels ADC Toward Phase 3 Trials

on

Regeneron Enters Radiopharma with $2.1B Biobucks Deal with Australia's Telix

on

FDA's Vinay Prasad to Depart as Head of Vaccines and Biologics Division Amid Controversy

on

Novo Nordisk Faces Double Departures: GLP-1 Expert Retires as Obesity Leader Joins Boehringer Ingelheim

on

FDA Rejects Replimune's RP1 Melanoma Treatment for Second Time, Citing Unresolved Trial Issues

on

Seaport Therapeutics and Hemab Therapeutics File for IPOs

on

Miltenyi Bio's CAR-T Clears Triple Autoimmune Burden in Single Patient

on

AilsynBio and Dong-E-E-Jiao Sign Project Cooperation Agreement Empowering Traditional Medicine with AI

on

Post-Hoc Live: Biopharma M&A Surge Signals Industry Revival

on